BLUE BELL, Pa., June 24 TheraQuest Biosciences, Inc., a clinical stage pain management company today announced the appointment of Dr. Danny Kao, PhD, JD, as Senior Vice President, Pharmaceutical Development and General Counsel and Douglas R. Baum, MS as Senior Vice President, Business Development. On June 22, 2010, TheraQuest unveiled its analgesic product pipeline and provided a status update on its lead programs in chronic pain and neuropathic pain.
Dr. Najib Babul, CEO, said, "We have added two seasoned executives with more than 30 years of combined analgesic drug development experience to our senior management team. The addition of outstanding, multi-talented pharma executives like Danny and Doug is a key step in TheraQuest's evolution as a company. Combined with our new product line-up, this move positions TheraQuest for significant progress in near future."
Biographical Summary of Management Team Additions
Danny Kao, PhD, JD joins TheraQuest as Senior Vice President, Pharmaceutical Development and General Counsel. Previously, Dr. Kao was Director, Strategic Development and Director, Formulation Development at Endo Pharmaceuticals. Dr. Kao has developed several extended release dosage forms, including first to file generic formulations bioequivalent to OxyContin® and MS Contin®. Dr. Kao received his master's degree in industrial pharmacy from the St. John's University, New York, his PhD in pharmaceutical sciences from the University of Kentucky and his JD from Touro College Law Center. Dr. Kao is a registered patent attorney at the USPTO and is admitted to practice law in New York and New Jersey.
Douglas R. Baum, MS joins TheraQuest as Senior Vice President, Business Development. Mr. Baum has been involved in analgesic drug development for over 20 years with SCIREX Corporation and with its new corporate entity, Premier Research Group. He has extensive business development experience, working across a number of classes and formulations of analgesics. Mr. Baum served as VP, Strategic Development in the Analgesia & Rheumatology at SCIREX and later as Senior VP, Early Development Unit and VP, Global Business Development at Premier Research. He has significant operational experience with P&L responsibility, having served as Project Director and Program Director in analgesia. Mr. Baum has authored over 20 scientific publications in the field of pain. He received his bachelor's and master's degree from the University of Texas at Austin.
SOURCE TheraQuest Biosciences, Inc.